Home GPCR & G Protein FPR

FPR

Other GPCR & G Protein Inhibitors

Hedgehog/Smoothened PKA CGRP Receptor Endothelin Receptor S1P Receptor Cannabinoid Receptor SGLT Opioid Receptor GPR CCR
Cat.No. Product Name Information Product Use Citations Product Validations
S9818 WRW4 WRW4 is a specific formyl peptide receptor-like 1 (FPRL1) antagonist that inhibits WKYMVm binding to FPRL1 with IC50 of 0.23 μM. This compound is a selective antagonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX).
Exp Mol Med, 2025, 57(9):2067-2082
Neurosci Res, 2025, 218:104932
In Vitro Cell Dev Biol Anim, 2025, 10.1007/s11626-024-01008-9
S0547 HCH6-1 HCH6-1 is a selective competitive antagonist of formyl peptide receptor 1 (FPR1) and has protective effects against acute lung injury (ALI). This compound may have potential as a new therapeutic agent for treating FPR1-involved inflammatory lung diseases.
Respir Res, 2025, 26(1):308
Signal Transduct Target Ther, 2024, 9(1):193.
E1313 N-Formyl-Met-Leu-Phe (fMLP) N-Formyl-Met-Leu-Phe (fMLP) is an endogenous chemotactic peptide and agonist for the formyl peptide receptor 1 (FPR1) with Ki of 38 nM. It stimulates aggregation of leukocytes.
Mater Today Bio, 2025, 31:101630
E7571 FPR Agonist 43 FPR Agonist 43 (Compound 43) is a potent synthetic dual agonist of FPR1 and FPR2/ALX receptors that promotes the resolution of inflammation and tissue repair by inducing receptor cross-desensitization to limit neutrophil migration and reduce pro-inflammatory cytokines like TNF-α.
E4628 BMS-986235 BMS-986235 (LAR-1219) is a selective, orally active and potent agonist of formyl peptide receptor 2 (FPR2), with EC50 values of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. This compound therapy shows promising improvements in cardiac structure and function in a mouse model of heart failure, highlighting its potential for preventing the progression of heart failure.